Inovio Pharmaceuticals, Inc.

NasdaqCM:INO 주식 보고서

시가총액: US$202.4m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Inovio Pharmaceuticals 관리

관리 기준 확인 3/4

Inovio Pharmaceuticals' CEO는 Jacqueline Shea, May2022 에 임명되었습니다 의 임기는 2.08 년입니다. 총 연간 보상은 $ 2.44M, 30.8% 로 구성됩니다. 30.8% 급여 및 69.2% 보너스(회사 주식 및 옵션 포함). 는 $ 288.02K 가치에 해당하는 회사 주식의 0.13% 직접 소유합니다. 288.02K. 경영진과 이사회의 평균 재임 기간은 각각 3.7 년과 5.6 년입니다.

주요 정보

Jacqueline Shea

최고 경영자

US$2.4m

총 보상

CEO 급여 비율30.8%
CEO 임기2.1yrs
CEO 소유권0.1%
경영진 평균 재임 기간3.7yrs
이사회 평균 재임 기간5.6yrs

최근 관리 업데이트

Recent updates

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

May 15
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

May 13
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Oct 23
Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Oct 13

Inovio Pharmaceuticals: Long On Promise, Short On Results

Sep 27

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Aug 09

Inovio: After All These Years

Jul 19

Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022

Apr 15

Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Mar 21
Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Inovio Undervalued On Potential 2022 Catalyst

Jan 26

Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Dec 31
Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side

Nov 18

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Sep 24
Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Inovio: Simply Cannot Be Ignored

Sep 03

Inovio Has 4 Sources Of Potential Value

Jun 23

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Jun 11
Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Inovio stock trades higher defying insider sale

Jun 07

CEO 보상 분석

Jacqueline Shea 의 보수는 Inovio Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$751k

-US$135m

Sep 30 2023n/an/a

-US$165m

Jun 30 2023n/an/a

-US$168m

Mar 31 2023n/an/a

-US$241m

Dec 31 2022US$4mUS$730k

-US$280m

Sep 30 2022n/an/a

-US$332m

Jun 30 2022n/an/a

-US$355m

Mar 31 2022n/an/a

-US$328m

Dec 31 2021US$2mUS$468k

-US$304m

Sep 30 2021n/an/a

-US$221m

Jun 30 2021n/an/a

-US$142m

Mar 31 2021n/an/a

-US$188m

Dec 31 2020US$2mUS$431k

-US$166m

Sep 30 2020n/an/a

-US$180m

Jun 30 2020n/an/a

-US$222m

Mar 31 2020n/an/a

-US$123m

Dec 31 2019US$1mUS$335k

-US$119m

보상 대 시장: Jacqueline 의 총 보상 ($USD 2.44M )은 US 시장( $USD 1.62M ).

보상과 수익: Jacqueline 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jacqueline Shea (58 yo)

2.1yrs

테뉴어

US$2,438,908

보상

Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...

리더십 팀

이름위치테뉴어보상소유권
Jacqueline Shea
CEO, President & Director2.1yrsUS$2.44m0.13%
$ 262.8k
Peter Kies
Chief Financial Officer22yrsUS$1.16m0.095%
$ 193.2k
Laurent Humeau
Chief Scientific Officer5.3yrsUS$1.14m0.094%
$ 190.1k
Thomas Hong
Manager of Investor Relationsno data데이터 없음데이터 없음
Robert Crotty
General Counsel & Chief Compliance Officer2.6yrs데이터 없음데이터 없음
E. Brandreth
Senior Vice President of Quality Assuranceno data데이터 없음데이터 없음
Jeffrey Skolnik
Senior Vice President of Clinical Development3.7yrs데이터 없음데이터 없음
Robert Juba
Senior Vice President of Biological Manufacturing & Clinical Supply Management3.7yrs데이터 없음데이터 없음
Stephen Kemmerrer
Senior Vice President of Engineering Developmentno data데이터 없음데이터 없음
Shawn Bridy
Senior Vice President of Business Development3.4yrs데이터 없음데이터 없음
Mark Twyman
Chief Commercial Officer3.7yrs데이터 없음데이터 없음
David Liebowitz
Senior Vice President of Early-Stage Clinical Developmentless than a year데이터 없음데이터 없음

3.7yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: INO 의 관리팀은 경험 ( 3.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Jacqueline Shea
CEO, President & Director2.1yrsUS$2.44m0.13%
$ 262.8k
Wendy Yarno
Independent Director6.5yrsUS$123.69k0.032%
$ 65.2k
Lota Zoth
Independent Director5.4yrsUS$118.69k0.025%
$ 51.2k
Jay Shepard
Independent Director4.4yrsUS$119.31k0.027%
$ 55.0k
Simon Benito
Independent Chairman of Board of Directors20.5yrsUS$151.19k0.039%
$ 78.3k
David B. Weiner
Chairman of the Scientific Advisory Board & Director24.4yrsUS$201.79k0.32%
$ 644.4k
Stanley Plotkin
Member of Scientific Advisory Board15yrs데이터 없음데이터 없음
Ann Miller
Independent Director5.3yrsUS$126.94k0.030%
$ 60.2k
Anthony Ford-Hutchinson
Member of Scientific Advisory Board12.3yrs데이터 없음데이터 없음
Roger Dansey
Independent Director3.1yrsUS$108.69k0.026%
$ 52.7k
Rafi Ahmed
Member of Scientific Advisory Board5.6yrs데이터 없음데이터 없음

5.6yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: INO 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.